Better Medtech Buy: J&J vs. Medtronic
If you're shopping for a healthcare stock that promises growth, the medical technology space could offer some good choices. Many suffered at certain points during the earlier days of the pandemic as hospitals postponed nonessential procedures, but since hospitals have resumed business as usual, revenue for these companies is picking up. In fact, some medtech players are even posting impressive growth.
Two giants in the space are Johnson Johnson (NYSE: JNJ) and Medtronic (NYSE: MDT). They bring in billions of dollars in earnings annually thanks to vast device portfolios and both of these companies could offer you share performance over time. But which one makes the better medtech buy right now? Let's find out.
J is a bit different from Medtronic because it isn't a device-only business. In fact, its biggest business is pharmaceuticals. But this healthcare giant's getting bigger and bigger in the medtech area. In the most recent earnings report, J's medtech business grew more than 14% on an operational basis -- surpassing growth of its pharma business.
Source Fool.com
Medtronic plc Aktie
Eine Tendenz zu Buy-Einschätzungen bei Medtronic plc, überwiegend gegenüber Sell-Einschätzungen.
Ein Kursziel von 94 € für Medtronic plc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 81.1 €.
